Home | Publications | Research (R&D) | Pipeline place holder
place holder place holder

Pipeline

Omrix Biopharmaceuticals, Inc. Product Pipeline Analysis


Publication Date   August 2008
Publisher   Global Markets Direct
Product Type   Report
Pages   48
ISBN Number   not applicable
Product Code   GMD731
Ask a question about this product?

Price £505.00

approximately: $753 | €602

Summary


This report is an insightful source for data, analysis and strategic insights into a Omrix Biopharmaceuticals, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

  • Details of development stage by sector and equipment type.
  • Pipeline products grouped by therapy area, development stage and trial phase.
  • Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
  • Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
  • Product updates covering estimated approval dates and estimated launch dates.
  • Descriptions of novel technologies relating to pipeline products of the company.
  • Patents and patent applications covered for the product.
  • News updates on key events relating to the product and its development.

Reasons to buy

  • A single source to fulfill competitor information relating to products in development.
  • Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

  • Access clinical trial information to map trial results and plan targeted marketing activities.
  • Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
  • Identification of potential investment opportunities.
  • Build up knowledge base for potential distribution and marketing partners.
  • Helps avoid patent infringement.
  • Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content


  • 1 List of Tables
    • 1.2 List of Figures
  • 2 Company Snapshot
    • 2.1 Key Information
    • 2.2 Company Overview
    • 2.3 Financial Performance
    • 2.4 Industry Outlook - In Vitro Diagnostics
  • 3 Business Description
    • 3.1 Business Overview
    • 3.2 Major Products and Services
      • 3.2.1 Overview
  • 4 Competitors
  • 5 Key Employees
  • 6 Key Employee Biographies
  • 7 Company Statement
  • 8 Locations And Subsidiaries
    • 8.1 Head Office
    • 8.2 Other Locations & Subsidiaries
  • 9 Recent Developments
    • 9.1 Financial Announcements
      • 9.1.1 Aug 11, 2008: Omrix Declares 2Q 2008 Results
      • 9.1.2 May 09, 2008: Omrix Declares Q1 2008 Results
      • 9.1.3 Mar 06, 2008: Omrix Declares Q4 2007 Results
      • 9.1.4 Nov 05, 2007: Omrix Declares Q3 2007 Results
      • 9.1.5 Aug 08, 2007: Omrix Declares Q2 2007 Results
      • 9.1.6 May 08, 2007: Omrix Declares Q1 2007 Results
      • 9.1.7 Mar 08, 2007: Omrix Declares Q4 2006 Results
      • 9.1.8 Nov 07, 2006: Omrix Declares Q3 2006 Results
    • 9.2 Corporate Communications
      • 9.2.1 Aug 11, 2008: Omrix Appoints New CFO
      • 9.2.2 May 15, 2008: Omrix Appoints New Chairman And Director
      • 9.2.3 Feb 01, 2008: Omrix Announces Senior Management Changes
      • 9.2.4 Aug 23, 2007: Omrix Appoints CFO
      • 9.2.5 Apr 05, 2007: Omrix Announces CFO Resignation
      • 9.2.6 Jan 19, 2007: Omrix Appoints New Board Members
    • 9.3 Product News
      • 9.3.1 Jul 25, 2008: Omrix Biopharmaceuticals Receives Positive Opinion From Committee For Medicinal Products For Human Use (CHMP) For Evicel Liquid Fibrin Sealant
      • 9.3.2 Mar 27, 2008: OMRIX Biopharmaceuticals Announces Initiation And First Patient Enrollment In Phase II Clinical Trial For Fibrin Patch Product Candidate
      • 9.3.3 Mar 17, 2008: OMRIX Biopharmaceuticals Provides Update On Fibrin Patch Product Candidate
      • 9.3.4 Jan 10, 2008: OMRIX Biopharmaceuticals Receives FDA Approval For General Hemostasis In Surgery Indication For EVICEL Liquid Fibrin Sealant (Human)
      • 9.3.5 Apr 03, 2007: Aeris Therapeutics Initiates Phase 2 Trial Of Biologic Lung Volume Reduction
    • 9.4 Product Approvals
      • 9.4.1 Jul 25, 2008: Omrix Biopharmaceuticals Receives Positive Opinion From Committee For Medicinal Products For Human Use (CHMP) For Evicel Liquid Fibrin Sealant
      • 9.4.2 Jan 10, 2008: OMRIX Biopharmaceuticals Receives FDA Approval For General Hemostasis In Surgery Indication For EVICEL Liquid Fibrin Sealant (Human)
    • 9.5 Clinical Trials
      • 9.5.1 Mar 27, 2008: OMRIX Biopharmaceuticals Announces Initiation And First Patient Enrollment In Phase II Clinical Trial For Fibrin Patch Product Candidate
      • 9.5.2 Mar 17, 2008: OMRIX Biopharmaceuticals Provides Update On Fibrin Patch Product Candidate
      • 9.5.3 Apr 03, 2007: Aeris Therapeutics Initiates Phase 2 Trial Of Biologic Lung Volume Reduction
  • 10 Omrix Biopharmaceuticals, Inc. Pipeline Products
    • 10.1 Omrix Biopharmaceuticals, Inc. Product Pipeline Analysis
      • 10.1.1 Omrix Biopharmaceuticals, Inc. Pipeline Products By Equipment Type
      • 10.1.2 Omrix Biopharmaceuticals, Inc. Pipeline Products By Development Stage
      • 10.1.3 Omrix Biopharmaceuticals, Inc. Pipeline Products By Therapy Area
      • 10.1.4 Omrix Biopharmaceuticals, Inc. Pipeline Products By Clinical Trials
      • 10.1.5 Omrix Biopharmaceuticals, Inc. Pipeline Products By News Summary
    • 10.2 Evicel
      • 10.2.1 Product Description
      • 10.2.2 Product Status
      • 10.2.3 Product Milestone
    • 10.3 Evithorm
      • 10.3.1 Product Description
      • 10.3.2 Product Status
    • 10.4 Fibrin Patch
      • 10.4.1 Product Description
      • 10.4.2 Product Status
      • 10.4.3 Clinical Trials
      • 10.4.4 Product Milestone
    • 10.5 Biologic Lung Volume Reduction System
      • 10.5.1 Product Description
      • 10.5.2 Product Status
      • 10.5.3 Clinical Trials
      • 10.5.4 Product Milestone
    • 10.6 Flowable thrombin
      • 10.6.1 Product Description
      • 10.6.2 Product Status
  • 11 Appendix
    • 11.1 Methodology
      • 11.1.1 Coverage
      • 11.1.2 Secondary Research
      • 11.1.3 Primary Research
      • 11.1.4 Expert Panel Validation
    • 11.2 Contact Us
    • 11.3 About Global Markets Direct
    • 11.4 Disclaimer
  • 1 List of Tables
    • Table 1: Omrix Biopharmaceuticals, Inc.,Key Facts
    • Table 2: Omrix Biopharmaceuticals, Inc., Key Employees,
    • Table 3: Omrix Biopharmaceuticals, Inc., Other Locations
    • Table 4: Omrix Biopharmaceuticals, Inc., Subsidiaries
    • Table 5: Omrix Biopharmaceuticals, Inc. Pipeline Products by Equipment Type
    • Table 6: Omrix Biopharmaceuticals, Inc. Pipeline Products By Development Stage
    • Table 7: Omrix Biopharmaceuticals, Inc. Pipeline Products By Therapy Area
    • Table 8: Omrix Biopharmaceuticals, Inc. Pipeline Products By Clinical Trials
    • Table 9: Omrix Biopharmaceuticals, Inc. Pipeline Products By News Summaries
    • 1.2 List of Figures
    • Figure 1: Omrix Biopharmaceuticals, Inc. Pipeline Products By Development Stage
    • Figure 2: Global Markets Direct Methodology